Faron Pharmaceuticals Oy (FARN):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Faron Pharmaceuticals Oy (FARN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8072
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:49
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:フィンランド
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Faron Pharmaceuticals Oy (Faron) is a clinical stage biopharmaceutical company that conducts clinical stage drug discovery and development. The company’s pipeline products focus on cute organ traumas, vascular damage and cancer immunotherapy. It offers Traumakine, that helps to prevent vascular leakage and organ failures and is the only treatment for acute respiratory distress syndrome (ARDS). Faron’s Clevegen is a pre-clinical anti-Clever-1 antibody that has the ability to switch immune suppression to immune activation in various conditions. The company’s Clevegen can be used for oncology, infectious disease and vaccine development. It partners with academic institutions and pharmaceutical companies. Faron is headquartered in Turku, Finland.

Faron Pharmaceuticals Oy (FARN) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Faron Pharmaceuticals Oy, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Faron Pharmaceuticals Oy, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Faron Pharmaceuticals Oy, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Faron Pharmaceuticals Oy, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Faron Pharmaceuticals Oy, Medical Devices Deals, 2012 to YTD 2018 9
Faron Pharmaceuticals Oy, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Faron Pharmaceuticals Oy, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
Faron Pharma Enters into Agreement with University of Birmingham Medical School 12
Faron Pharma Enters into Agreement with Selexis 13
Faron Pharma Enters into Joint Development Partnership with Turku PET Center 14
Licensing Agreements 15
Pharmbio Korea Enters into Licensing Agreement with Faron Pharma 15
China Medical System Enters into Licensing Agreement with Faron Pharma 16
Equity Offering 17
Faron Pharma Raises USD10 Million in Second Tranche of Private Placement of Shares 17
Faron Pharma Raises USD0.5 Million in Second Tranche of Rights Offering of Shares 19
Faron Pharma Raises USD13.3 Million in Private Placement of Shares 20
Faron Pharma Raises USD11.9 Million in Private Placement of Shares 21
Faron Pharma Raises USD1.3 Million in Rights Offering of Shares 22
Faron Pharma to Raise USD0.1 Million in Private Placement of Shares upon Exercise of Warrants 23
Faron Pharma Raises USD0.3 Million in Private Placement of Shares 24
Faron Pharma Raises USD6 Million in Private Placement of Shares 25
Faron Pharma Raises USD10.4 Million in Private Placement of Shares 26
Faron Pharma Raises Funds in IPO 28
Acquisition 29
A&B Acquires 15.72% Stake in Faron Pharma for USD5.6 Million 29
Faron Pharmaceuticals Oy – Key Competitors 30
Faron Pharmaceuticals Oy – Key Employees 31
Faron Pharmaceuticals Oy – Locations And Subsidiaries 32
Head Office 32
Recent Developments 33
Financial Announcements 33
Sep 13, 2018: Faron Pharmaceuticals: Interim results for the six months ended 30 June 2018 33
May 08, 2018: Faron Pharmaceuticals: Final Results for the year ended 31 December 2017 38
Sep 06, 2017: Faron Pharmaceuticals: Interim Results for the six months ended 30 June 2017 39
Mar 29, 2017: Faron Pharmaceuticals: Final Results for the year ended 31 December 2016 40
Feb 09, 2017: Faron update for 2017 46
Corporate Communications 47
Dec 01, 2017: Faron Pharmaceuticals Oy: Appointment of Chief Commercial Officer 47
Apr 19, 2017: Faron Pharmaceuticals: Proposed Board Changes 48
Appendix 49
Methodology 49
About GlobalData 49
Contact Us 49
Disclaimer 49

List of Tables
Faron Pharmaceuticals Oy, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Faron Pharmaceuticals Oy, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Faron Pharmaceuticals Oy, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Faron Pharmaceuticals Oy, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Faron Pharmaceuticals Oy, Deals By Therapy Area, 2012 to YTD 2018 8
Faron Pharmaceuticals Oy, Medical Devices Deals, 2012 to YTD 2018 9
Faron Pharmaceuticals Oy, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Faron Pharma Enters into Agreement with University of Birmingham Medical School 12
Faron Pharma Enters into Agreement with Selexis 13
Faron Pharma Enters into Joint Development Partnership with Turku PET Center 14
Pharmbio Korea Enters into Licensing Agreement with Faron Pharma 15
China Medical System Enters into Licensing Agreement with Faron Pharma 16
Faron Pharma Raises USD10 Million in Second Tranche of Private Placement of Shares 17
Faron Pharma Raises USD0.5 Million in Second Tranche of Rights Offering of Shares 19
Faron Pharma Raises USD13.3 Million in Private Placement of Shares 20
Faron Pharma Raises USD11.9 Million in Private Placement of Shares 21
Faron Pharma Raises USD1.3 Million in Rights Offering of Shares 22
Faron Pharma to Raise USD0.1 Million in Private Placement of Shares upon Exercise of Warrants 23
Faron Pharma Raises USD0.3 Million in Private Placement of Shares 24
Faron Pharma Raises USD6 Million in Private Placement of Shares 25
Faron Pharma Raises USD10.4 Million in Private Placement of Shares 26
Faron Pharma Raises Funds in IPO 28
A&B Acquires 15.72% Stake in Faron Pharma for USD5.6 Million 29
Faron Pharmaceuticals Oy, Key Competitors 30
Faron Pharmaceuticals Oy, Key Employees 31

List of Figures
Faron Pharmaceuticals Oy, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Faron Pharmaceuticals Oy, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Faron Pharmaceuticals Oy, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Faron Pharmaceuticals Oy, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Faron Pharmaceuticals Oy, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Faron Pharmaceuticals Oy, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Faron Pharmaceuticals Oy, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Faron Pharmaceuticals Oy, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Faron Pharmaceuticals Oy, Medical Devices Deals, 2012 to YTD 2018 9

★海外企業調査レポート[Faron Pharmaceuticals Oy (FARN):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Singulex Inc:医療機器:M&Aディール及び事業提携情報
    Summary Singulex Inc (Singulex) is a medical device company develops single molecule counting technology. The company provides Sgx clarity system, an in vitro diagnostics platform that provides high sensitivity next generation immunodiagnostics. Its proprietary SMC technology allows scientists and p …
  • GarrettCom, Inc.:企業の戦略的SWOT分析
    GarrettCom, Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servi …
  • Kohinoor Energy Limited (KOHE):企業の財務・戦略的SWOT分析
    Kohinoor Energy Limited (KOHE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • The Credit Mutuel-Cic Group:企業の戦略・SWOT・財務分析
    The Credit Mutuel-Cic Group - Strategy, SWOT and Corporate Finance Report Summary The Credit Mutuel-Cic Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Central Japan Railway Company:企業の戦略・SWOT・財務情報
    Central Japan Railway Company - Strategy, SWOT and Corporate Finance Report Summary Central Japan Railway Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • GCL System Integration Technology Co Ltd (002506):電力:M&Aディール及び事業提携情報
    Summary GCL System Integration Technology Co Ltd (GCL System Integration), formerly Shanghai Chaori Solar Energy Science & Technology Co Ltd, a subsidiary of Golden Concord Holdings Ltd, is a renewable energy company that offers clean and sustainable power production services. The company's products …
  • Alcon Laboratories Inc:医療機器:M&Aディール及び事業提携情報
    Summary Alcon Laboratories Inc (Alcon), a division of Novartis AG, develops and manufactures devices in the field of ophthalmology. The company’s portfolio encompasses contact lenses and surgical products. Alcon’s products are used for the treatment of various conditions such as cataracts, glaucoma, …
  • Pedernales Electric Cooperative, Inc.:企業の発電所・SWOT分析2018
    Pedernales Electric Cooperative, Inc. - Power Plants and SWOT Analysis, 2018 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, informatio …
  • United States Postal Service:企業の戦略的SWOT分析
    United States Postal Service - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produc …
  • Alchemia Ltd (ACL):製薬・医療:M&Aディール及び事業提携情報
    Summary Alchemia Ltd (Alchemia) is an early stage biopharmaceutical company that focuses on the discovery and development of drugs for the treatment of various diseases. It sold the worldwide exclusive intellectual property rights to its product, Fondaparinux sodium (a generic version of the anticoa …
  • Culture Landmark Investment Ltd:企業の戦略・SWOT・財務分析
    Culture Landmark Investment Ltd - Strategy, SWOT and Corporate Finance Report Summary Culture Landmark Investment Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Simons Group Ltd:企業の戦略・SWOT・財務分析
    Simons Group Ltd - Strategy, SWOT and Corporate Finance Report Summary Simons Group Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Allianz Seguros SA:企業の戦略・SWOT・財務分析
    Allianz Seguros SA - Strategy, SWOT and Corporate Finance Report Summary Allianz Seguros SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • HLS Therapeutics Inc (HLS):製薬・医療:M&Aディール及び事業提携情報
    Summary HLS Therapeutics Inc (HLS Therapeutics) is a pharmaceutical company that offers central nervous system and cardiovascular therapeutic products. The company's product includes clozaril, absorica, vascepa and trinomial. Its clozapine is a pharmaceutical product used in the treatment of schizop …
  • San Leon Energy Plc (SLE):企業の財務・戦略的SWOT分析
    Summary San Leon Energy Plc (San Leon) is an oil and gas exploration and production company. It is engaged in acquiring, exploring and developing conventional and shale oil and gas assets across Europe and North Africa. The company holds interests in Durresi Block located in offshore Albania and inc …
  • Suncor Energy Inc (SU):電力:M&Aディール及び事業提携情報
    Summary Suncor Energy Inc. (Suncor) is an integrated energy company that mainly focuses on the development of Athabasca oil sands. It carries out development and up gradation of oil sands; offshore and onshore oil and gas production; refining of crude oil and marketing of petroleum and petrochemical …
  • Insmed Inc (INSM):医療機器:M&Aディール及び事業提携情報
    Summary Insmed Inc (Insmed) is a biopharmaceutical company that focuses on rare diseases. Its lead product candidate, Arikayce (liposomal amikacin for inhalation), is indicated for the treatment of nontuberculous mycobacteria (NTM) lung disease in adult patients. Its other clinical pipeline are bein …
  • Hon Hai Precision Industry Co Ltd (2317):企業の財務・戦略的SWOT分析
    Hon Hai Precision Industry Co Ltd (2317) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths …
  • Lumosa Therapeutics Co Ltd (6535):製薬・医療:M&Aディール及び事業提携情報
    Summary Lumosa Therapeutics Co Ltd (Lumosa Therapeutics) is a developer of drugs for the treatment of neurological and inflammatory diseases. The company’s pipeline products include LT-1001, an analgesic injection for severe pain relief; and LT-3001, a novel small molecule for acute ischemic stroke. …
  • Industrial and Commercial Bank of China Ltd:企業のM&A・事業提携・投資動向
    Industrial and Commercial Bank of China Ltd - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Industrial and Commercial Bank of China Ltd Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, det …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆